Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Essentra trading in line with expectations

(Sharecast News) - Essentra said in an update on Wednesday that trading remained in line with expectations in the first four months of 2025, as group revenue declined 1.3% on a like-for-like and trading day adjusted basis. The London-listed company, which was holding its annual general meeting, highlighted an improvement in order intake during the period, led by the EMEA region, and said its full-year expectations remain unchanged.

Regional performance continued to diverge, with mid-single digit volume declines in EMEA moderating compared to late 2024.

The Americas returned to low-single digit volume growth, while Asia-Pacific sustained its positive momentum with mid-single digit growth, supported by China's exports to the wider region.

Essentra said it was largely insulated from direct tariff impacts due to its regional manufacturing and sales model, with the majority of products made and sold within the same region.

Incremental tariff-related costs were being passed on, with further mitigation efforts, including supply chain redirection, underway.

Essentra reiterated its confidence in delivering on its medium-term financial and strategic targets.

It said it was continuing to invest selectively in growth opportunities and operational initiatives, while remaining alert to potential bolt-on acquisitions that support long-term value creation.

At 1100 BST, shares in Essentra were up 1.8% at 102p.

Reporting by Josh White for Sharecast.com.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.